Vitamin K2

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: bones heart longevity

Research Overview

Across the abstracts, vitamin K2 (menaquinones, e.g., MK-4 to MK-13; most commonly MK-4 and MK-7) is studied primarily in relation to extrahepatic vitamin K–dependent protein carboxylation and its downstream implications for bone and vascular biology. The most frequently examined areas are (i) osteoporosis and bone remodeling (osteoblast/osteoclast regulation via pathways such as BMP/Smad, Wnt/β-catenin, and RANKL/OPG), (ii) vascular calcification prevention through activation (carboxylation) of matrix Gla protein (MGP), and (iii) clinical contexts where vitamin K metabolism is perturbed by anticoagulation—especially vitamin K antagonists (VKAs) in high-risk populations such as hemodialysis patients with atrial fibrillation. A recurring theme is that “vitamin K” is not a single entity: different isoforms (K1 vs K2; and among K2, different menaquinones) have distinct kinetics, tissue distribution, and bioavailability, complicating synthesis of evidence and generalization across studies.

The strongest evidence in these abstracts supports mechanistic plausibility and biomarker-level effects rather than definitive disease-outcome prevention in the general population. At the mechanistic level, K2’s role as a cofactor for γ-glutamylcarboxylase is well established, enabling activation of extrahepatic proteins relevant to calcification control (e.g., MGP). In hemodialysis patients, randomized data indicate that VKA therapy worsens functional vitamin K status (increased dp-ucMGP), while switching to rivaroxaban reduces dp-ucMGP, and adding vitamin K2 reduces it further—supporting a consistent effect of K2 supplementation on vitamin K–dependent calcification-related biomarkers in this setting. For bone, preclinical evidence (e.g., diabetic osteoporosis models) suggests K2 can attenuate high-glucose–associated bone loss and ferroptosis via AMPK/SIRT1 signaling with downstream effects on GPX4 and osteogenic markers; broader reviews also summarize pro-osteogenic and anti-osteoclastogenic signaling effects. However, the broader review-level conclusion remains that current knowledge is insufficient to make decisive claims that K2 prevents osteoporosis or cardiovascular disease outcomes across populations.

Key gaps needing more research include: (i) adequately powered, long-duration randomized controlled trials testing clinically meaningful endpoints (fractures, bone mineral density trajectories, cardiovascular events, and imaging-defined vascular calcification progression) rather than primarily biomarkers; (ii) head-to-head comparisons of K2 isoforms (notably MK-4 vs MK-7) with standardized dosing, pharmacokinetics, and tissue-specific endpoints; (iii) clearer delineation of which patient subgroups benefit most (e.g., diabetes-related bone disease, chronic kidney disease/hemodialysis, VKA-exposed patients) and how baseline vitamin K status modifies response; and (iv) improved integration of safety and interaction data, particularly in anticoagulated patients, given the clinical relevance of vitamin K pathways and the heterogeneity of “vitamin K” compounds. Overall, the literature summarized here supports strong biological rationale and promising signals in specific high-risk contexts, but indicates that definitive preventive or therapeutic claims for K2 on major bone and cardiovascular outcomes remain incompletely established.

1. What conditions has Vitamin K2 been studied for?

  • Bone health / osteoporosis (prevention and treatment): Multiple reviews discuss vitamin K2 (menaquinones, especially MK-4 and MK-7) in relation to osteoporosis risk and bone remodeling pathways.

  • Type 2 diabetic osteoporosis (T2DOP): An animal + cell study tested vitamin K2 in a streptozotocin-induced diabetic osteoporosis mouse model and high-glucose cell culture model.

  • Vascular calcification / cardiovascular disease risk: Reviews discuss K2’s role in carboxylating matrix Gla protein (MGP), a key inhibitor of vascular calcification. A randomized trial in hemodialysis patients evaluated vascular calcification progression and cardiovascular outcomes with rivaroxaban ± vitamin K2 vs vitamin K antagonists.

  • Atrial fibrillation anticoagulation context in hemodialysis: In the Valkyrie study program, vitamin K2 was tested as an add-on to rivaroxaban (not as an anticoagulant itself) in hemodialysis patients with atrial fibrillation.

  • Osteoarthritis (OA): A rat OA model and in vitro chondrocyte oxidative injury model tested vitamin K2 for pain, cartilage/subchondral bone changes, and ferroptosis-related mechanisms.

  • Other proposed areas (less directly evidenced in the provided abstracts): One review claims MK-7 has been studied in atherosclerosis, cancer, and inflammatory diseases; another mentions age-related conditions (e.g., dementia, frailty) as areas of interest, but details are truncated and not supported with specific trial outcomes in the provided text.

2. Does it work in treating those conditions? Summarize the evidence.

  • Osteoporosis (general): mixed/insufficient for decisive conclusions

    • A broad review notes that despite extensive research into vitamin K and prevention of osteoporosis/cardiovascular disease, “current knowledge does not allow us to make a decisive conclusion,” in part because “vitamin K” includes multiple forms (K1, various K2 menaquinones, and synthetic forms) with different kinetics and biological activity.

    • Other reviews describe plausible mechanisms (e.g., osteoblast signaling pathways; carboxylation of vitamin K–dependent proteins) and suggest K2 “holds promise” as part of nutritional supplementation for osteoporosis prevention, but these are not definitive treatment-effect conclusions.

  • Type 2 diabetic osteoporosis (T2DOP): positive preclinical evidence

    • In a mouse T2DOP model and high-glucose BMSC model, vitamin K2 inhibited high-glucose–mediated bone loss and markers of ferroptosis (lower mitochondrial ROS, lipid peroxidation, malondialdehyde; higher glutathione) and increased expression of SIRT1, GPX4, and osteogenic markers.

    • Mechanistically, the study reports activation of AMPK/SIRT1 signaling; SIRT1 knockdown prevented the beneficial effects in vitro, supporting causality in that model.

    • Limitation: these are animal/cell findings; they do not establish clinical efficacy in humans with diabetes-related osteoporosis.

  • Osteoarthritis: positive preclinical evidence

    • In an ACLT-induced rat OA model and oxidative-damage chondrocyte model, vitamin K2 improved pain-related behavior (Von Frey), increased subchondral bone mass and cartilage thickness, and reduced OA severity scores (OARSI).

    • Mechanisms proposed include “dual-target” regulation of GPX4, increased GSH and GSH/GSSG ratio, reduced MDA, inhibition of chondrocyte ferroptosis, and reduced MAPK/NFκB pathway activation leading to less ECM degradation.

    • Limitation: preclinical; not proof of benefit in human OA.

  • Vascular calcification in hemodialysis: improved vitamin K status but no clear calcification benefit

    • In hemodialysis patients with atrial fibrillation, high-dose vitamin K2 (given with rivaroxaban) improved vitamin K status biomarkers: baseline dp-ucMGP was “severely elevated”; VKAs increased dp-ucMGP, while dp-ucMGP decreased in rivaroxaban and decreased more with rivaroxaban + vitamin K2 (though remained elevated).

    • However, changes in coronary artery, thoracic aorta, and cardiac valve calcium scores and pulse wave velocity were not significantly different among treatment arms, and clinical event rates were similar across groups in that report.

    • Interpretation: in this high-risk population, improving vitamin K status with K2 did not translate into measurable slowing of vascular calcification progression over the study period.

  • Cardiovascular outcomes in hemodialysis anticoagulation trials: unclear incremental benefit of adding K2

    • In the Valkyrie study, reduced-dose rivaroxaban (with or without vitamin K2) reduced a composite of fatal/nonfatal cardiovascular events and major bleeding compared with VKA therapy. The abstracts provided do not clearly isolate the incremental clinical benefit of adding vitamin K2 on top of rivaroxaban for outcomes (the main contrast emphasized is rivaroxaban vs VKA).

    • Limitation: the trial context is anticoagulation choice; vitamin K2 is an adjunct and not the primary driver of anticoagulation efficacy.

3. What health benefits does it have?

  • Activation of vitamin K–dependent proteins beyond coagulation

    • Vitamin K is required for post-translational modification (carboxylation) of multiple proteins; beyond the 7 coagulation proteins, it is also involved in maturation of “another 11 or 12 proteins” implicated in connective tissue calcification regulation.

  • Potential bone benefits (mechanistic + preclinical support)

    • Reviews describe vitamin K2 (MK-4, MK-7) as promoting osteoblast development via pathways including BMP/Smad and Wnt/β-catenin, and as shifting osteoclast regulation by reducing RANKL signaling and increasing OPG (reducing the RANKL/OPG ratio).

    • In T2DOP models, vitamin K2 improved bone mass and osteogenic markers and reduced ferroptosis via AMPK/SIRT1 and GPX4-related antioxidant defenses.

  • Potential vascular benefits (biological plausibility; limited clinical confirmation in provided abstracts)

    • Vitamin K2 may help prevent vascular calcification by activating matrix Gla protein (MGP) through carboxylation (mechanistic rationale highlighted in reviews).

    • In hemodialysis patients, vitamin K2 improved dp-ucMGP (a functional vitamin K deficiency marker), indicating improved vitamin K status, though calcification progression was not significantly altered in that study.

  • Potential osteoarthritis benefits (preclinical)

    • In OA models, vitamin K2 reduced pain behavior and slowed cartilage/ECM degradation, associated with reduced ferroptosis and inflammatory signaling (MAPK/NFκB) via GPX4-related mechanisms.

  • Pharmacokinetic advantages of certain K2 forms (especially MK-7)

    • Reviews emphasize that K1 vs K2 differ in absorption, tissue distribution, and bioavailability; menaquinones may be more effective at activating extra-hepatic vitamin K–dependent proteins than phylloquinone.

4. Does it have any downsides or side effects?

  • Evidence in the provided abstracts suggests low toxicity/overdose concern, but data are limited

    • One review states that vitamin K2 (MK-7) has been studied “without risk of negative side effects or overdosing.” However, this is a general claim in a review and is not supported by specific adverse-event rates in the provided text.

    • Another review explicitly discusses “detection, and toxicity” of different vitamin K forms, implying that safety/toxicity depends on the form and kinetics, but the abstract does not provide specific toxicity findings.

  • Interaction considerations with anticoagulation (important practical downside)

    • Vitamin K antagonists (VKAs) worsen functional vitamin K status (dp-ucMGP increased with VKA initiation/continuation). While this is not a “side effect” of K2, it highlights that vitamin K biology is tightly linked to anticoagulation management.

    • The abstracts do not provide direct evidence of harm from vitamin K2 supplementation in anticoagulated patients, but in practice vitamin K intake can affect VKA dosing stability; this specific point is not tested directly in the provided abstracts.

  • Clinical outcome limitations (a “downside” in terms of expectations)

    • In hemodialysis patients, improving vitamin K status with high-dose K2 did not significantly slow vascular calcification progression, suggesting that biomarker improvement may not translate into clinical benefit in all populations/settings.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses or genotype-specific effects of vitamin K2 (e.g., variants in VKORC1, GGCX, or other vitamin K pathway genes). Therefore:

  • No direct evidence here that vitamin K2 is beneficial or harmful for specific genetic variants.

  • Key limitation: while vitamin K biology is closely tied to pathways that have known genetic influences (especially in anticoagulation with VKAs), these abstracts do not evaluate whether genetic variation modifies response to vitamin K2 supplementation.

References

  1. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity.
    Přemysl Mladěnka, Kateřina Macáková, Lenka Kujovská Krčmová, Lenka Javorská, Kristýna Mrštná, Alejandro Carazo, Michele Protti, Fernando Remião, Lucie Nováková (2022) - Nutrition reviews
  2. A Novel Anti-Osteoporosis Mechanism of VK2: Interfering with Ferroptosis via AMPK/SIRT1 Pathway in Type 2 Diabetic Osteoporosis.
    Chen Jin, Kai Tan, Zhe Yao, Bing-Hao Lin, Du-Piao Zhang, Wei-Kai Chen, Shu-Ming Mao, Wei Zhang, Liang Chen, Zhen Lin, She-Ji Weng, Bing-Li Bai, Wen-Hao Zheng, Gang Zheng, Zong-Yi Wu, Lei Yang (2023) - Journal of agricultural and food chemistry
  3. Role of vitamins beyond vitamin D
    Anatoly V Skalny, Michael Aschner, Aristidis Tsatsakis, Joao B T Rocha, Abel Santamaria, Demetrios A Spandidos, Airton C Martins, Rongzhu Lu, Tatiana V Korobeinikova, Wen Chen, Jung-Su Chang, Jane C J Chao, Chong Li, Alexey A Tinkov (2024) - International journal of molecular medicine
  4. Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review.
    Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, Norliza Muhammad (2024) - Biomedicines
  5. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease.
    Maurice Halder, Ploingarm Petsophonsakul, Asim Cengiz Akbulut, Angelina Pavlic, Frode Bohan, Eric Anderson, Katarzyna Maresz, Rafael Kramann, Leon Schurgers (2019) - International journal of molecular sciences
  6. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
    An S De Vriese, Rogier Caluwé, Hans Van Der Meersch, Koen De Boeck, Dirk De Bacquer (2021) - Journal of the American Society of Nephrology : JASN
  7. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
    An S De Vriese, Rogier Caluwé, Lotte Pyfferoen, Dirk De Bacquer, Koen De Boeck, Joost Delanote, Didier De Surgeloose, Piet Van Hoenacker, Bruno Van Vlem, Francis Verbeke (2020) - Journal of the American Society of Nephrology : JASN
  8. Vitamin K2 ameliorates osteoarthritis by suppressing ferroptosis and extracellular matrix degradation through activation GPX4's dual functions.
    Qi He, Yuewei Lin, Baihao Chen, Chuyi Chen, Jiaxu Zeng, Xiangyun Dou, Dongling Cai, Chi Zhou, Haibin Wang (2024) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. The role of menaquinones (vitamin K₂) in human health.
    Joline W J Beulens, Sarah L Booth, Ellen G H M van den Heuvel, Elisabeth Stoecklin, Athanasia Baka, Cees Vermeer (2013) - The British journal of nutrition
  10. Vitamin K as a Diet Supplement with Impact in Human Health: Current Evidence in Age-Related Diseases.
    Dina C Simes, Carla S B Viegas, Nuna Araújo, Catarina Marreiros (2020) - Nutrients
  11. Calcium, vitamin D, vitamin K2, and magnesium supplementation and skeletal health.
    Anna Capozzi, Giovanni Scambia, Stefano Lello (2020) - Maturitas
  12. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
    Marjo H J Knapen, Lavienja A J L M Braam, Nadja E Drummen, Otto Bekers, Arnold P G Hoeks, Cees Vermeer (2015) - Thrombosis and haemostasis
  13. Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities.
    Nikita Jadhav, Saiprasad Ajgaonkar, Praful Saha, Pranay Gurav, Amitkumar Pandey, Vivek Basudkar, Yash Gada, Sangita Panda, Shashank Jadhav, Dilip Mehta, Sujit Nair (2022) - Frontiers in pharmacology
  14. Vitamin K2 stimulates MC3T3‑E1 osteoblast differentiation and mineralization through autophagy induction.
    Weiwei Li, Shaokun Zhang, Jie Liu, Yongyi Liu, Qingwei Liang (2019) - Molecular medicine reports
  15. The biological responses of vitamin K2: A comprehensive review.
    Quanxiang Yan, Tao Zhang, Christine O'Connor, James W Barlow, John Walsh, Gaia Scalabrino, Feng Xu, Helen Sheridan (2023) - Food science & nutrition
  16. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials.
    Ming-Ling Ma, Zi-Jian Ma, Yi-Lang He, Hao Sun, Bin Yang, Bin-Jia Ruan, Wan-da Zhan, Shi-Xuan Li, Hui Dong, Yong-Xiang Wang (2022) - Frontiers in public health
  17. Vitamin K2 in Health and Disease: A Clinical Perspective.
    Tao Zhang, Christine O'Connor, Helen Sheridan, James W Barlow (2024) - Foods (Basel, Switzerland)
  18. Vitamin K‑dependent proteins involved in bone and cardiovascular health (Review).
    Lianpu Wen, Jiepeng Chen, Lili Duan, Shuzhuang Li (2018) - Molecular medicine reports
  19. Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial.
    Ornina Atieh, Joviane Daher, Jared C Durieux, Marc Abboud, Danielle Labbato, Jhony Baissary, Ziad Koberssy, Kate Ailstock, Morgan Cummings, Nicholas T Funderburg, Grace A McComsey (2025) - Nutrients
  20. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
    M H J Knapen, N E Drummen, E Smit, C Vermeer, E Theuwissen (2013) - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!